Mineralys Therapeutics, Inc. - Common Stock (MLYS)

Historical Holders from Q1 2023 to Q3 2025

Symbol
MLYS on Nasdaq
Type / Class
Equity / Common Stock
Shares outstanding
77,392,610
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
79,306,949
Holdings value
$3,007,317,130
% of all portfolios
0.016%
Number of holders
191
Number of buys
109
Number of sells
-78
Average buys %
+0%
Average sells %
-0.01%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Mineralys Therapeutics, Inc. - Common Stock (MLYS)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Catalys Pacific Fund, LP 13.5% $129,027,569 8,978,954 Catalys Pacific Fund, LP 30 Jun 2025
RA CAPITAL MANAGEMENT, L.P. 9.9% 0% $104,939,988 +$20,308,933 7,796,433 +24% RA Capital Management, L.P. 04 Sep 2025
Samsara BioCapital, L.P. 8.2% -10% $85,419,771 +$8,209,106 6,346,194 +10.6% Srinivas Akkaraju 04 Sep 2025
Andera Partners 4.2% $39,747,075 2,765,976 Andera Partners 30 Jun 2025
ADAMS STREET PARTNERS LLC 2.3% $15,320,183 1,129,807 Adams Street Partners, LLC 31 Dec 2024

Institutional Holders of Mineralys Therapeutics, Inc. - Common Stock (MLYS)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 79,306,949 $3,007,317,130 +$505,416,563 $37.92 191
2025 Q2 65,687,280 $888,767,559 +$52,640,107 $13.53 164
2025 Q1 61,178,854 $971,385,613 +$245,430,113 $15.88 148
2024 Q4 46,486,259 $572,248,542 +$24,847,746 $12.31 108
2024 Q3 44,382,325 $540,052,185 +$2,379,010 $12.11 105
2024 Q2 44,151,028 $516,569,023 +$24,151,320 $11.7 93
2024 Q1 41,871,642 $540,562,541 +$93,970,804 $12.91 91
2023 Q4 34,713,391 $298,534,855 -$5,432,193 $8.6 87
2023 Q3 26,512,068 $252,135,025 -$9,247,223 $9.51 77
2023 Q2 25,186,898 $429,224,695 +$10,759,767 $17.05 68
2023 Q1 24,614,198 $385,431,208 +$385,431,208 $15.66 66